share_log

Silo Pharma And 3 Other Stocks Under $5 Insiders Are Buying

Silo Pharma And 3 Other Stocks Under $5 Insiders Are Buying

內部人士正在買入Silo Pharma和其他3只低於5美元的股票
Benzinga ·  04/02 19:39

The Dow Jones index closed lower by over 200 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

道瓊斯指數週一收盤下跌超過200點。當內部人士購買或出售股票時，這表明他們對公司前景的信心或擔憂。對細價股感興趣的投資者和交易者可以將此視爲他們整體投資或交易決策的一個因素。

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

以下是近期一些值得注意的細價股內幕交易。欲了解更多，請查看 本辛加的內幕交易 平台。

Alzamend Neuro

Alzamend Neuro

  • The Trade: Alzamend Neuro, Inc. (NASDAQ:ALZN) Director Milton C Ault III acquired a total of 2,000 shares an average price of $1.06. To acquire these shares, it cost around $2,127..
  • What's Happening: On Dec. 11, 2023, Alzamend Neuro received a "Study May Proceed" letter from the FDA for the initiation of study AL001-PTSD01, a Phase 2A study of AL001 for post-traumatic stress disorder (PTSD).
  • What Alzamend Neuro Does: Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's.
  • 交易：Alzamend Neuro, Inc.（納斯達克股票代碼：ALZN）董事 Milton C Ault III 共收購了 2,000 股股份 平均價格爲1.06美元。收購這些股票的成本約爲2,127美元。
  • 發生了什麼：2023年12月11日，Alzamend Neuro收到了美國食品藥品管理局的 “研究可能繼續” 的信，要求啓動研究 AL001-PTSD01，這是一項針對創傷後應激障礙（PTSD）AL001 的2A期研究。
  • Alzamend Neuro做什麼：Alzamend Neuro Inc是一家處於早期臨床階段的生物製藥公司。它專注於開發用於治療神經退行性疾病和精神疾病（包括阿爾茨海默氏症）的新產品。

Gain Therapeutics

Gain 療法

  • The Trade: Gain Therapeutics, Inc. (NASDAQ:GANX) Director Jeffrey Scott Riley acquired a total of 30,000 shares at at an average price of $3.86. To acquire these shares, it cost around $115,770.
  • What's Happening: Gain Therapeutics, named Jonas Hannestad, M.D., Ph.D. as its chief medical officer, effective as of March 25, 2024.
  • What Gain Therapeutics Does: Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology.
  • 交易：Gain Therapeutics, Inc.（納斯達克股票代碼：GANX）董事傑弗裏·斯科特·萊利 共收購了 30,000 股股票 平均價格爲3.86美元。收購這些股票的成本約爲115,770美元。
  • 發生了什麼：Gain Therapeutics任命醫學博士喬納斯·漢內斯塔德爲首席醫學官，自2024年3月25日起生效。
  • Gain Therapeutics的作用：Gain Therapeutics Inc是一家生物技術公司，開發新的小分子療法，用於治療多個治療領域的疾病，包括溶酶體貯積症、中樞神經系統疾病、代謝障礙和腫瘤學。

Azitra

阿齊特拉

  • The Trade: Azitra, Inc. (NYSE:AZTR) CFO Norm Staskey acquired a total of 47,600 shares at an average price of $0.21. The insider spent around $10,034 to buy those shares.
  • What's Happening: On March 15, Azitra announced a FY23 loss of $1.83 per share.
  • What Azitra Does: Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products that can be applied topically to treat diseases of the skin.
  • 貿易：阿齊特拉公司（紐約證券交易所代碼：AZTR）首席財務官諾姆·斯塔斯基 共收購了47,600股股票 平均價格爲0.21美元。知情人士花費了約10,034美元購買了這些股票。
  • 發生了什麼：3月15日，阿齊特拉宣佈23財年每股虧損1.83美元。
  • Azitra做什麼：Azitra Inc是一家早期臨床生物製藥公司，專注於使用工程蛋白和可局部應用於治療皮膚疾病的活生物治療產品開發精準皮膚病療法。

Silo Pharma

思洛製藥

  • The Trade: Silo Pharma, Inc. (NASDAQ:SILO) President and CEO Eric Weisblum acquired a total of 4,508 shares at an average price of $1.93. The insider spent around $8,713 to buy those shares.
  • What's Happening: On Feb. 28, Silo Pharma completed successful dose-ranging study of SPC-15 intranasal therapeutic for PTSD.
  • What Silo Pharma Does: SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases.
  • 交易：Silo Pharma, Inc.（納斯達克股票代碼：SILO）總裁兼首席執行官埃裏克·魏斯布魯姆 共收購了4,508股股票 平均價格爲1.93美元。知情人士花費了約8,713美元購買了這些股票。
  • 發生了什麼：2月28日，Silo Pharma成功完成了創傷後應激障礙的 SPC-15 鼻內治療劑量範圍研究。
  • Silo Pharma做什麼：SILO Pharma Inc是一家處於發展階段的生物製藥公司，正在開發新療法，以解決服務不足的疾病，包括壓力誘發的精神疾病、慢性疼痛和中樞神經系統（CNS）疾病。

Don't forget to check out our premarket coverage here

別忘了在這裏查看我們的上市前報道

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論